Bionano Genomics- Warrants (21/08/2023) P/E Ratio

Bionano Genomics- Warrants (21/08/2023) (BNGOW) currently reports a P/E ratio of -0.46. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore Bionano Genomics- Warrants (21/08/2023)'s P/E ratio history and peer comparisons.

Bionano Genomics- Warrants (21/08/2023)'s P/E ratio of -0.46 is lower than the Healthcare sector average of 25.3. That is roughly 101.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Bionano Genomics- Warrants (21/08/2023)'s market price to a fundamental measure such as earnings, sales, or book value. At -0.46, BNGOW can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.46, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Bionano Genomics- Warrants (21/08/2023), and consider following BNGOW for alerts when major investors trade the stock.

Bionano Genomics- Warrants (21/08/2023) is classified in the Healthcare sector. On P/E ratio, it currently shows -0.46 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BNGOW with unrelated industries.